Yamaguchi Keizo, Ishii Yoshikazu, Tateda Kazuhiro, Iwata Morihiro, Watanabe Naoki, Shinagawa Masaaki, Kayaba Hiroyuki, Kimura Masahiko, Suwabe Akira, Kaku Mitsuo, Abe Yuko, Kanemitsu Keiji, Taniguchi Nobuyuki, Murakami Masami, Maesaki Shigefumi, Kawamura Toru, Nomura Fumio, Watanabe Masaharu, Kanno Harushige, Horiuchi Hajime, Tazawa Yoko, Kondo Shigemi, Misawa Shigeki, Takemura Hiromu, Nakashima Hideki, Matsuto Takayuki, Fujimoto Yoshinori, Ishigo Shiomi, Gotoh Hirokazu, Watanabe Osamu, Yagi Tetsuya, Shimaoka Nami, Mikamo Hiroshige, Yamagishi Yuka, Fujita Naohisa, Komori Toshiaki, Ichiyama Satoshi, Kawano Seiji, Nakayama Akifumi, Nakamura Fumihiko, Kohno Hisashi, Fukuda Saori, Kusano Nobuchika, Nose Motoko, Yokozaki Michiya, Onodera Makoto, Murao Koji, Negayama Kiyoshi, Nishimiya Tatsuya, Miyamoto Hitoshi, Matsunaga Akira, Yoshimura Hisae, Kohno Shigeru, Yanagihara Katsunori, Hiramatsu Kazufumi
Jpn J Antibiot. 2014 Apr;67(2):73-107.
The nationwide surveillance of antibacterial susceptibility to meropenem (MEPM) and other parenteral antibiotics against clinical isolates during 2012 in Japan was conducted. A total of 2985 strains including 955 strains of Gram-positive bacteria, 1782 strains of Gram-negative bacteria, and 248 strains of anaerobic bacteria obtained from 31 medical institutions were examined. The results were as follows; 1. MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA). 2. Of all species tested, there were no species, which MIC90 of MEPM was more than 4-fold higher than those in our previous studies in 2009 or 2006. Therefore, the tendency to increase in antimicrobial resistance rates was not observed. 3. MEPM resistance against Pseudomonas aeruginosa was 17.8% (56/315 strains). Compared to our previous results, it was the lowest than that in 2006 and 2009. 4. Carbapenem-resistant Klebsiella pneumoniae, and multi-drug-resistant Acinetobacter species, which emerged in worldwide, were not observed. 5. The proportion of extended-spectrum beta-lactamase (ESBL) strains was 6.2% (59/951 strains) in enterobacteriaceae, which increased compared with that of our previous studies in 2009 or before. Whereas, the proportion of metallo-beta-lactamase strains was 1.6% (5/315 strains) in P. aeruginosa, which was stable. In conclusion, the results from this surveillance suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem for serious infections treatment at present, 17 years passed after available for commercial use in Japan.
2012年，日本开展了针对临床分离菌株对美罗培南（MEPM）及其他注射用抗生素的全国性抗菌药敏监测。对从31家医疗机构获取的总共2985株菌株进行了检测，其中包括955株革兰氏阳性菌、1782株革兰氏阴性菌和248株厌氧菌。结果如下：1. 与其他受试碳青霉烯类抗生素相比，MEPM对革兰氏阴性菌，尤其是肠杆菌科细菌和流感嗜血杆菌的活性更强。MEPM对大多数受试革兰氏阳性菌和厌氧菌也有活性，但对包括耐甲氧西林金黄色葡萄球菌（MRSA）在内的多重耐药菌株除外。2. 在所有受试菌种中，没有任何一种菌种的MEPM MIC90比我们2009年或2006年之前的研究结果高出4倍以上。因此，未观察到耐药率上升的趋势。3. 铜绿假单胞菌对MEPM的耐药率为17.8%（56/315株）。与我们之前的结果相比，这是2006年和2009年以来的最低水平。4. 未观察到在全球范围内出现的耐碳青霉烯类肺炎克雷伯菌和多重耐药不动杆菌属菌种。5. 肠杆菌科中广谱β-内酰胺酶（ESBL）菌株的比例为6.2%（59/951株），与我们2009年或之前的研究相比有所增加。而铜绿假单胞菌中金属β-内酰胺酶菌株的比例为1.6%（5/315株），较为稳定。总之，本次监测结果表明，MEPM在日本上市17年后，目前仍保留其强大而广泛的抗菌活性，因此是治疗严重感染的一种临床有用的碳青霉烯类药物。
